Recommendations for permanent prostate brachytherapy with 131Cs: A consensus report from the Cesium Advisory Group

Brachytherapy

Volumn 7, Issue 4, 2008, Pages 290-296

  Bice, William S ^a,b   Prestidge, Bradley R ^b,c   Kurtzman, Steven M ^d   Beriwal, Sushil ^e   Moran, Brian J ^f   Patel, Rakesh R ^g   Rivard, Mark J ^h  

^a Foundation for Medical Physics Research   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Texas Cancer Clinic   (United States)

^d SUTTER HEALTH   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f Prostate Cancer Foundation of Chicago   (United States)

^g UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^h TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cesium; Clinical results; Dosimetry; Implants; Prostate brachytherapy

Indexed keywords

CESIUM; CESIUM 131; IODINE 125; PALLADIUM 103; UNCLASSIFIED DRUG;

ARTICLE; BRACHYTHERAPY; CONSENSUS; EDEMA; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MEDICAL PRACTICE; MEDICAL SOCIETY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECTUM; URETHRA;

BRACHYTHERAPY; CESIUM RADIOISOTOPES; DOSE-RESPONSE RELATIONSHIP, RADIATION; EDEMA; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 53349162245     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2008.05.004     Document Type: Article

References (34)

1. Armpilia C.I., Dale R.G., Coles I.P., et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys 55 (2003) 378-385
2. Prestidge B.R., Bice W.S., Jurkovic I., et al. Cesium-131 permanent prostate brachytherapy: an initial report. Int J Radiat Oncol Biol Phys 63 (2005) S336-S337
3. Prestidge B.R., Bice W.S., Jurkovic J., et al. A multi-institutional phase II trial for cesium-131 permanent prostate brachytherapy. Brachytherapy 5 (2006) 79
4. Bice W.S., and Prestidge B.R. Cesium-131 permanent prostate brachytherapy: the dosimetric analysis of a multi-institutional phase II trial. Brachytherapy 6 (2007) 88-89
5. Prestidge B.R., and Bice W.S. Clinical outcomes of a phase II, multi-institutional cesium-131 permanent prostate brachytherapy trial. Brachytherapy 6 (2007) 78
6. 131Cs source. Med Phys 34 (Feb 2007) 754-762
7. 131Cs brachytherapy sources recommended dosimetry data. Personal communication. Richland, WA: IsoRayMedical; 2007.
8. Dale RG. Comparison of the radiobiological effects of Cs-131 implants with those associated with I-125 and Pd-103 implants. Personal communication. Richland, WA: IsoRayMedical; 2004.
9. Yue N., Heron D.E., Komanduri K., et al. Prescription dose in permanent (131)Cs seed prostate implants. Med Phys 32 (Aug 2005) 2496-2502
10. Murphy M.K., Piper R.K., Greenwood L.R., et al. Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy. Med Phys 31 (Jun 2004) 1529-1538
11. Chen Z., Bongiorni P., and Nath R. Dose rate constant of a cesium-131 interstitial brachytherapy seed measured by thermoluminescent dosimetry and gamma-ray spectrometry. Med Phys 32 (Nov 2005) 3279-3285
12. Wittman R.S., and Fisher D.R. Multiple-estimate Monte Carlo calculation of the dose rate constant for a cesium-131 interstitial brachytherapy seed. Med Phys 34 (Jan 2007) 49-54
13. Brenner DJ. Estimation of optimal Cs-131 boost dose for combined external-beam/boost treatment for prostate cancer; 2005.
14. NUREG1556. Consolidated guidance about materials licenses. Program-specific guidance about medical use licenses. 2002;9:U1-U27.
15. 10 CFR35. Medical use of byproduct material: part 35.75 release of individuals containing unsealed byproduct material or implants containing byproduct material; 2007.
16. Prestidge B.R., Bice W.S., Kiefer E.J., et al. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 40 (1998) 1111-1115
17. Waterman F.M., Yue N., Corn B.W., et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: an analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 41 (1998) 1069-1077
18. 103Pd seed implant of prostate. Int J Radiat Oncol Biol Phys 43 (1999) 447-454
19. Speight J.L., Shinohara K., Pickett B., et al. Prostate volume change after radioactive seed implantation: possible benefit of improved dose volume histogram with perioperative steroid. Int J Radiat Oncol Biol Phys 48 (2000) 1461-1467
20. 131Cs (model CS-1) seeds. Med Phys 33 (2006) 968-975
21. Wang J.Z., Mayr N.A., Nag S., et al. Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy. Med Phys 33 (Apr 2006) 1025-1032
22. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 605-614
23. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
24. 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 50 (2001) 335-341
25. 103Pd brachytherapy seeds. J Res Natl Inst Stand Technol 108 (2003) 337-358
26. 125I interstitial brachytherapy. Med Phys 32 (May 2005) 1424-1439
27. 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription. Med Phys 27 (Apr 2000) 634-642
28. Beyer D., Nath R., Butler W., et al. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 47 (2000) 273-275
29. Rivard M.J., Butler W.M., Devlin P.M., et al. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy 6 (2007) 34-37
30. Merrick G.S., Butler W.M., Tollenaar B.G., et al. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 52 (2002) 461-468
31. Wallner K., Roy J., and Harrison L. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 32 (1995) 465-471
32. RegGuide8.39. Release of patients administered radioactive materials (1997), NRC, USA 1-19
33. Horwitz E.M., Vicini F.A., Ziaja E.L., et al. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. Int J Radiat Oncol Biol Phys 41 (1998) 267-272
34. Kuban D.A., Levy L.B., Potters L., et al. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 65 (2006) 1487-1493